Stay updated on DTG/3TC in HIV-1 Adolescents Clinical Trial
Sign up to get notified when there's something new on the DTG/3TC in HIV-1 Adolescents Clinical Trial page.

Latest updates to the DTG/3TC in HIV-1 Adolescents Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe study record for the dolutegravir/lamivudine trial in treatment-naive adolescents is displayed, including its design, eligibility criteria, outcome measures, results-related details, and study documents.SummaryDifference69%

- Check20 days agoChange DetectedThe site footer revision changes from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide banner announces NIH website updates and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check34 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer’s ClinicalTrials.gov revision indicator changes from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the typical study-record content with an error screen and leaving only generic header/footer information visible.SummaryDifference21%

Stay in the know with updates to DTG/3TC in HIV-1 Adolescents Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DTG/3TC in HIV-1 Adolescents Clinical Trial page.